Does the media prefer LKFT or CGON?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 5 articles in the media. CG Oncology's average media sentiment score of 0.94 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.31 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Is LKFT or COGT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Cogent Biosciences N/A -84.47% -47.72%

Is LKFT or ERAS more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Erasca N/A -38.43% -32.05%

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$27.99 +0.47 (+1.71%)

As of 08/18/2026 04:00 PM Eastern

Compare

LKFT vs. CGON, SRRK, MIRM, COGT, and ERAS

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? Lakefront Biotherapeutics American Depositary Shares's main competitors and comparable companies include CG Oncology (CGON), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 5 articles in the media. CG Oncology's average media sentiment score of 0.94 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.31 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $30.67, suggesting a potential upside of 9.56%. CG Oncology has a consensus target price of $83.18, suggesting a potential upside of 9.03%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, equities analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
CG Oncology	-3,602.68%	-25.20%	-23.98%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A
CG Oncology	$4.04M	1,673.85	-$160.99M	-$2.69	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

In the previous week, Scholar Rock had 4 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 9 mentions for Scholar Rock and 5 mentions for Lakefront Biotherapeutics American Depositary Shares. Scholar Rock's average media sentiment score of 0.40 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.31 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock currently has a consensus price target of $57.71, suggesting a potential upside of 5.47%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $30.67, suggesting a potential upside of 9.56%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Scholar Rock. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A

Summary

Scholar Rock beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Mirum Pharmaceuticals currently has a consensus target price of $137.33, indicating a potential upside of 36.15%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $30.67, indicating a potential upside of 9.56%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Mirum Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 5 mentions for Lakefront Biotherapeutics American Depositary Shares. Mirum Pharmaceuticals' average media sentiment score of 0.50 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.31 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.56	-$23.36M	-$14.55	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Cogent Biosciences had 2 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 7 mentions for Cogent Biosciences and 5 mentions for Lakefront Biotherapeutics American Depositary Shares. Cogent Biosciences' average media sentiment score of 1.23 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.31 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Cogent Biosciences	N/A	-84.47%	-47.72%

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Cogent Biosciences. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $30.67, indicating a potential upside of 9.56%. Cogent Biosciences has a consensus price target of $49.40, indicating a potential upside of 32.09%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

Cogent Biosciences beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Erasca?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $30.67, suggesting a potential upside of 9.56%. Erasca has a consensus target price of $22.09, suggesting a potential upside of 22.05%. Given Erasca's stronger consensus rating and higher possible upside, analysts clearly believe Erasca is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Erasca	N/A	-38.43%	-32.05%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Erasca had 14 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 19 mentions for Erasca and 5 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.31 beat Erasca's score of 0.13 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Erasca. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$363.05M	-$1.41	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

Erasca beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.81B	$3.74B	$7.06B	$13.09B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-19.85	11.65	270.28	24.33
Price / Sales	1.47	1,369.54	629.46	105.24
Price / Cash	37.92	44.90	28.88	38.50
Price / Book	0.59	17.48	11.19	6.43
Net Income	$363.05M	-$12.50M	$3.46B	$348.18M
7 Day Performance	0.21%	1.00%	0.85%	-0.08%
1 Month Performance	-6.73%	3.18%	2.55%	1.47%
1 Year Performance	-12.80%	59.17%	26.81%	21.05%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	1.374 of 5 stars	$27.99 +1.7%	$30.67 +9.6%	-14.9%	$1.81B	$1.26B	N/A	1,310	News Coverage
CGON CG Oncology	2.5279 of 5 stars	$75.89 -1.6%	$83.18 +9.6%	+192.0%	$6.73B	$6.23M	N/A	61
SRRK Scholar Rock	1.6801 of 5 stars	$53.64 +3.0%	$57.71 +7.6%	+73.6%	$6.53B	N/A	N/A	140
MIRM Mirum Pharmaceuticals	3.2922 of 5 stars	$100.47 +0.6%	$137.33 +36.7%	+51.3%	$6.52B	$618.07M	N/A	140	Analyst Downgrade
COGT Cogent Biosciences	2.7324 of 5 stars	$37.22 -1.7%	$49.40 +32.7%	+208.8%	$6.46B	N/A	N/A	80	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. CGON, SRRK, MIRM, COGT, and ERAS

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. CGON, SRRK, MIRM, COGT, and ERAS

How does Lakefront Biotherapeutics American Depositary Shares compare to CG Oncology?

Does the media prefer LKFT or CGON?

Which has more risk and volatility, LKFT or CGON?

Do analysts recommend LKFT or CGON?

Is LKFT or CGON more profitable?

Do insiders and institutionals have more ownership in LKFT or CGON?

Which has higher earnings and valuation, LKFT or CGON?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Scholar Rock?

Do insiders and institutionals hold more shares of SRRK or LKFT?

Which has more risk and volatility, SRRK or LKFT?

Is SRRK or LKFT more profitable?

Does the media refer more to SRRK or LKFT?

Do analysts prefer SRRK or LKFT?

Which has preferable earnings and valuation, SRRK or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Is MIRM or LKFT more profitable?

Do analysts recommend MIRM or LKFT?

Does the media refer more to MIRM or LKFT?

Which has stronger valuation & earnings, MIRM or LKFT?

Do institutionals and insiders have more ownership in MIRM or LKFT?

Which has more volatility and risk, MIRM or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Cogent Biosciences?

Does the media prefer LKFT or COGT?

Do insiders & institutionals believe in LKFT or COGT?

Which has more volatility and risk, LKFT or COGT?

Is LKFT or COGT more profitable?

Which has higher valuation and earnings, LKFT or COGT?

Do analysts rate LKFT or COGT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Erasca?

Do analysts prefer LKFT or ERAS?

Which has more volatility & risk, LKFT or ERAS?

Is LKFT or ERAS more profitable?

Do insiders & institutionals hold more shares of LKFT or ERAS?

Does the media prefer LKFT or ERAS?

Which has stronger valuation & earnings, LKFT or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools